Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933073 · ClinicalTrials.gov registry record · Phase 1
Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
A Phase 1 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02933073 is a Phase 1 study that was terminated before completion, run by UConn Health. The registered enrollment target is 8 participants.
The verdict
NCT02933073, a Phase 1 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase I trial to test the safety and feasibility of OncoImmunome vaccine in stage III/IV ovarian cancer patients. OncoImmunome is a tumor specific vaccine formulation which is predicted to elicit tumor-protective immune responses. A total of 15 patients will be enrolled from the Principal Investigator (PI) clinical practice. These patients will have just successfully completed standard of care surgical debulking with preservation of fresh tumor, chemotherapy treatment and be in documented clinical remission prior to receiving the vaccine. The patients receive 6-monthly doses of the vaccine and are monitored for up to 5 years post vaccination. This is a personalized vaccine, unique to each patient and is the "first in human" use.
Interventions
- BIOLOGICAL OncoImmunome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-11 |
| Est. Completion | 2022-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933073
The ClinicalTrials.gov registry entry for NCT02933073 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OncoImmunome is the first listed.
NCT02933073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02933073 about?
NCT02933073 is a clinical study titled "Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma". This is a Phase I trial to test the safety and feasibility of OncoImmunome vaccine in stage III/IV ovarian cancer patients. OncoImmunome is a tumor specific vaccine formulation which is predicted to elicit tumor-protective immune responses. A total of 15 patients will be enrolled from the Principal ...
What is the current status of trial NCT02933073?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-11. Estimated completion is 2022-08.
What interventions are being tested in trial NCT02933073?
The interventions under investigation include: OncoImmunome (BIOLOGICAL).
Who is sponsoring clinical trial NCT02933073?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.